ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Takeda ditches late-stage Ninlaro trial pharmatimes
June 11, 2019Takeda has announced the premature ending of its Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis, due to the study not meeting the first of two primary endpoints.
Pharma Sources Insight January 2025
